EVX-04
/ Evaxion
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 06, 2025
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
(GlobeNewswire)
- "EVX-04 induces targeted immune responses and prevents tumor growth in preclinical models EVX-04 is an off-the-shelf therapeutic cancer vaccine developed for acute myeloid leukemia....The new data confirms that all 16 ERV fragments included in EVX-04 elicit a specific immune response and that EVX-04 prevents tumor growth in preclinical tumor models."
Preclinical • Acute Myelogenous Leukemia
1 to 1
Of
1
Go to page
1